Immunovant, Inc. As pioneers in anti FcRn technology, Immunovant develops innovative and targeted therapies to meet the complex and varying needs of those with autoimmune conditions. Their two investigational products, batoclimab and IMVT-1402, are fully human monoclonal antibodies that specifically target FcRn and aim to reduce harmful immunoglobulin G (IgG) autoantibodies, which are prevalent in autoimmune diseases.

These product candidates have potential applications for a range of IgG-mediated autoimmune diseases, with subcutaneous injections that can be tailored based on disease stage and severity. Immunovant is driven by the vision of enabling normal lives for people with autoimmune diseases, and their values include trailblazing, agility, and collaboration. With a team of dedicated scientists, clinicians, and biopharma experts, Immunovant is committed to creating value and bringing new, transformative ideas to life for individuals battling autoimmune conditions